Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Non-Current Assets: 2013-2024

Historic Non-Current Assets for Fortress Biotech (FBIO) over the last 12 years, with Dec 2024 value amounting to $53.9 million.

  • Fortress Biotech's Non-Current Assets rose 54.15% to $62.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.9 million, marking a year-over-year increase of 54.15%. This contributed to the annual value of $53.9 million for FY2024, which is 6.63% up from last year.
  • Latest data reveals that Fortress Biotech reported Non-Current Assets of $53.9 million as of FY2024, which was up 6.63% from $50.5 million recorded in FY2023.
  • In the past 5 years, Fortress Biotech's Non-Current Assets ranged from a high of $67.3 million in FY2020 and a low of $50.0 million during FY2021.
  • In the last 3 years, Fortress Biotech's Non-Current Assets had a median value of $53.9 million in 2024 and averaged $56.1 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first declined by 25.60% in 2021, then increased by 27.63% in 2022.
  • Over the past 5 years, Fortress Biotech's Non-Current Assets (Yearly) stood at $67.3 million in 2020, then fell by 25.60% to $50.0 million in 2021, then increased by 27.63% to $63.9 million in 2022, then declined by 20.93% to $50.5 million in 2023, then increased by 6.63% to $53.9 million in 2024.